|Articles|January 12, 2009

Office of Inspector General Report

Office of Inspector General's report on the FDA's oversight of clinical investigators' financial information.

The U.S. Department of Health and Human Services' Office of Inspector General has published a report, "The Food and Drug Administration's Oversight of Clinical Investigators' Financial Information," which can be found at:

http://oig.hhs.gov/oei/reports/oei-01-07-00450.pdf

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Trending on Applied Clinical Trials Online

Office of Inspector General Report

Related Content

How to Tell Substance from Branding in Biotech's Support Ecosystem

ACT Brief: Lean Development Through Fractional Teams and Partners, FDA Expedited IND Pilot for Phase I Acceleration, and Tudriqev Accelerated Approval for Anti-PD-1-Refractory Melanoma

FDA Makes Case for Overhauling Early Clinical Development to Reclaim US Leadership

What a Lean Development Model Actually Means for Biotech Operations Today

ACT Brief: Commercial Strategy Shaping Early Clinical Development, Real-Time Trials Require Operational Infrastructure, and AI Site Engagement Gap

Trending on Applied Clinical Trials Online

Real-Time Trials Need More Than AI: Why Operational Trial Infrastructure Matters

ACT Brief: Commercial Strategy Shaping Early Clinical Development, Real-Time Trials Require Operational Infrastructure, and AI Site Engagement Gap

ACT Brief: Funding Gaps and Indication Decisions in Early-Stage Programs, Recruitment Funnel Leak Diagnosis, and Mega-Merger Speculation Denial

FDA Makes Case for Overhauling Early Clinical Development to Reclaim US Leadership

You've Been Spending Recruitment Money at the Wrong End of the Funnel